News Releases

Taiho Pharmaceutical's press releases may contain information about prescription drugs including products currently under development, however information contained in the press releases are not intended to constitute promotion, advertisement, or medical advice.

Site search

2014

December 24, 2014

Taiho Pharmaceutical Completes Submission of TAS-102 New Drug Application to the US Food and Drug Administration for the Treatment of Refractory Metastatic Colorectal Cancer
December 18, 2014

Antitumor Agent "Abraxane_® I.V. Infusion 100 mg" Approved for Additional Indication of Unresectable Pancreatic Cancer
October 21, 2014

Taiho Pharmaceutical Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer
- Taiho Initiates Rolling NDA Submission for TAS-102 -
July 31, 2014

Taiho Pharmaceutical Announces Termination of Phase III Clinical Trial of the Angiogenesis Inhibitor TSU-68 (orantinib) in Patients with Hepatocellular Carcinoma
July 25, 2014

Phase III Clinical Study of S-1 in Patients with Advanced Hepatocellular Carcinoma Did Not Meet Its Primary Endpoint
July 23, 2014

Taiho Pharmaceutical Invests US$ 30 Million in Remiges BioPharma Fund, LP to Foster Early Biotech Start-ups
July 02, 2014

Application for the Additional Indication of Febrile Neutropenia for ZOSYN_®, an Injectable Antibiotic Combined with β-Lactamase Inhibitor
June 30, 2014

Taiho Pharmaceutical Announces Results from TAS-102 Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer
June 11, 2014

Taiho Pharmaceutical Announces Personnel Changes（PDF：131.7 KB）
June 04, 2014

Data from Phase II Trial of ET-743 (trabectedin), a Novel Antitumor Agent, in Patients with Malignant Soft Tissue Sarcoma Presented at ASCO^®
June 03, 2014

Results of Phase III Clinical Study (SELECT BC) of TS-1 Treatment for Metastatic Breast Cancer Announced at ASCO^®
May 23, 2014

Anticancer Drug Lonsurf^® Combination Tablet Receives NHI Reimbursement Price Listing and is Scheduled for Launch
May 12, 2014

Taiho Oncology's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer
April 22, 2014

ET-743 (trabectedin), a Novel Antitumor Agent Meets Primary Endpoint of Progression Free Survival Prolongation in a Phase 2 Trial in Malignant Soft Tissue Sarcoma Patients
March 24, 2014

Taiho's Lonsurf^® (trifluridine and tipiracil hydrochloride) Tablets Approved in Japan for Treatment in Advanced Metastatic Colorectal Cancer
January 06, 2014

Transfer of Astellas' Fermentation Research-Related Assets to Taiho Pharmaceutical （PDF：152.6 KB）

News Releases

Select year from the Back Number